ACRV
Acrivon Therapeutics, Inc. Common StockNASDAQ
Healthcare • Biotechnology
Factor tilt: Micro-Cap Value
$1.61+2.55%
Close Nov 6, 2026
- Market cap
- $67.37M
- 1 month
- -13.9%
- 3 months
- -7.5%
- 1 year
- -20.7%
- 52-week range
- $1.29$3.01
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.44Quarter to Sep 30, 2026 · 5 analysts · 0.0% in 30d
- Short interest
- 6.7% of float1.7M shares · settled Oct 15, 2026 · +7.5% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$74.23M
- Free cash flow
- -$64.14M
- Book value
- $86.67M
- Total debt
- $2.12M
- P/E
- —
- Price / sales
- —
- Price / book
- 0.8×
- FCF yield
- -95.2%
- Net margin
- —
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
Read more
The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
- Website
- acrivon.com
- Headquarters
- Watertown, MA, United States
- Employees
- 74
- Listed
- Nov 15, 2022
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 27, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 12, 2026 | — | — | — | -$18.7M | -$18.0M |
| Mar 2026filed May 13, 2026 | — | — | — | -$19.9M | -$19.0M |
| Dec 2025filed Mar 19, 2026 | — | — | — | -$20.1M | -$19.0M |
| Sep 2025filed Nov 13, 2025 | — | — | — | -$19.7M | -$18.2M |
| Jun 2025filed Aug 13, 2025 | — | — | — | -$22.6M | -$21.0M |
| Mar 2025filed May 14, 2025 | — | — | — | -$21.7M | -$19.7M |
| Dec 2024filed Mar 27, 2025 | $848.0K | -55.0% | — | -$25.0M | -$22.8M |
| Sep 2024filed Nov 13, 2024 | — | — | — | -$25.1M | -$22.4M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 19, 2026 | — | — | — | -$84.1M | -$77.9M |
| Dec 2024filed Mar 27, 2025 | — | — | — | -$89.2M | -$80.6M |
| Dec 2023filed Mar 28, 2024 | — | — | — | -$67.2M | -$60.4M |
| Dec 2022filed Mar 28, 2023 | — | — | — | -$32.7M | -$29.7M |
| Dec 2021filed Dec 31, 2021 | — | — | — | -$16.2M | -$16.2M |
| Dec 2020filed Dec 31, 2020 | — | — | — | -$3.2M | -$5.3M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched ACRV. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
1,737,689 shares short
+120,962 shares (+7.5%) vs Sep 30, 2026
6.7% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
1,616,727 shares short
+414,108 shares (+34.4%) vs Sep 15, 2026
6.3% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
1,202,619 shares short
+63,382 shares (+5.6%) vs Aug 31, 2026
4.3% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
1,139,237 shares short
-96,656 shares (-7.8%) vs Aug 14, 2026
4.1% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
1,235,893 shares short
-119,122 shares (-8.8%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
1,355,015 shares short
-132,430 shares (-8.9%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind ACRV’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if ACRV is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
11 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Smart-money 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 12 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
45 filers reported a long position in ACRV for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
93.9%
of the 21.4M shares 13-F filers reported
Moves vs Q1 2026
8 added1 trimmed
1 unchanged
Net shares held
+33.8%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | $21.8M · 12.2M shares | 12.2M | +46.6% |
| 2 | Sands Capital Alternatives, LLC | $4.1M · 2.3M shares | 2.3M | +7.9% |
| 3 | ACADIAN ASSET MANAGEMENT LLC | $2.1M · 1.2M shares | 1.2M | +37.7% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $1.7M · 952K shares | 952K | +31.9% |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | $1.6M · 888.1K shares | 888.1K | Unchanged |
| 6 | RENAISSANCE TECHNOLOGIES LLC | $1.4M · 758.9K shares | 758.9K | +0.1% |
| 7 | TWO SIGMA INVESTMENTS, LP | $1.1M · 641.5K shares | 641.5K | +64.7% |
| 8 | MARSHALL WACE, LLP | $946.7K · 531.9K shares | 531.9K | -5.1% |
| 9 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | $674.4K · 378.9K shares | 378.9K | +138.5% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | $472.3K · 265.2K shares | 265.2K | +12.2% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of ACRV file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Aug 13, 2026 | Sands Capital Life Sciences Pulse Fund II LP13G · passive · amended | 5.3% |
| May 15, 2026 | CITADEL ADVISORS LLC13G · passive · amended | 0%under 5% |
| Apr 23, 2026 | RA CAPITAL MANAGEMENT, L.P.13D · activist · amended | 28.8% |
Get the Full Analysis for ACRV
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.